al to the volume-weighted average closing price of the shares for the 20 trading days ending the day prior to each installment due date, not to exceed $0.15. If the Company's common shares trade at or above $0.20, however, the option to receive payment in shares or cash is at T&T's discretion. The Company may also prepay all or any part of the Debenture in cash or stock at any time without penalty, subject to certain terms and conditions. For additional details of the Debenture and Settlement, please see the Interim Financial Report filed with www.otcmarkets.com
and the Company's periodic financial reports.
"Our HIV/AIDS technology and intellectual property portfolio have grown considerably in these last five years. We are now free to pursue possible partnerships and joint ventures at a much higher level that better reflect the value of the work," said Monica Ord, Senior Vice President, Viral Genetics. "Our relationships in Africa are more substantial than ever before and this settlement allows us to resume work in a country that desperately needs an effective treatment for AIDS. We are excited to move forward!"
About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers and develops drug therapies. Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant tumors. A majority-owned subsidiary called VG Energy is dedicated to exploring biofuel and agricultural applications for one of the technologies in its licensed portfolio. Online at www.viralgenetics.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by VPage: 1 2 3 Related biology technology :1
. A mix of tiny gold and viral particles -- and the DNA ties that bind them2
. Cellectis Meganuclease Technology Used to Efficiently Prevent Viral Infection3
. Nanotrope, Inc. Receives Patent on New Diagnostic Test for Influenza and Other Viral Infections4
. Roche Diabetes Care Forms Human Blue Circle, Supports Viral Video for World Diabetes Day5
. NVHR: Stop Liver Cancer Dead in Its Tracks By Closing Funding Gap for Viral Hepatitis Education, Screening Programs6
. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference7
. FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better8
. Viral Genetics Lead Scientist Dr. M. Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference9
. Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting10
. Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases11
. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue